Al-Ola Abdallah, Associate Professor and Plasma Cell Disorder Program Director of the Division of HMCT at the University of Kansas Medical Center, shared a post on LinkedIn:
” A simple comparison of Teclistamab studies in relapsed multiple myeloma—single agent vs combination therapy, and early vs late relapse settings.”
